Meconium Drug Screen

Overview

  • EPIC Code:
  • LAB2639
  • Soft Test Code:
  • MSOT
  • Send Out Test Code:
  • 45489
Alternate Names
  • Drug Screen Panel 5, Meconium [454X]
  • 454
  • Drug Screen Panel 5, Meconium
Included Tests

Amphetamines; Cocaine Metabolite; Marijuana; Phencyclidine; Opiates


Clinical Significance

Meconium contains the amniotic fluid swallowed by the fetus in the last half of pregnancy and is released as the first stools after birth. Meconium is easier to collect than neonatal urine and provides a much longer window of exposure of up to 20 weeks. Meconium is an effective biological marker of in utero drug exposure, and can provide insights leading to improved neonatal outcomes, as well as provide evidence to ensure appropriate rehabilitation of mothers suffering from addiction. The test is a screening assay using a homogeneous enzyme immunoassay method of analysis. Presumptive positive screen results are reflexed to a more specific and sensitive mass spectroscopy (MS) methodology. Test results equal to or greater than cutoff are reported as positive and results less than cutoff are reported as negative. Quantitative values cannot be used to assess the amount of drug that the neonate was exposed.


Specimen Collection & Preparation

Specimen Requirements:

-OR-

5 grams Meconium in a Sterile Plastic Container
Minimum Volume:
1 gram meconium*

* This volume does not allow for repeat testing

Specimen Information:


Transport and Storage:
  • Ambient (18-24°C): 48 Hours
  • Refrigerated (2-8°C): 7 Days

    Transport (Cold Packs)

  • Frozen (-20° C or colder): 30 Days

Clinical Interpretation

Reference Range:

See Laboratory Report


Methodology:
  • Immunoassay (IA) w/ Chromatography / Mass Spectrometry
Clinical Significance

Meconium contains the amniotic fluid swallowed by the fetus in the last half of pregnancy and is released as the first stools after birth. Meconium is easier to collect than neonatal urine and provides a much longer window of exposure of up to 20 weeks. Meconium is an effective biological marker of in utero drug exposure, and can provide insights leading to improved neonatal outcomes, as well as provide evidence to ensure appropriate rehabilitation of mothers suffering from addiction. The test is a screening assay using a homogeneous enzyme immunoassay method of analysis. Presumptive positive screen results are reflexed to a more specific and sensitive mass spectroscopy (MS) methodology. Test results equal to or greater than cutoff are reported as positive and results less than cutoff are reported as negative. Quantitative values cannot be used to assess the amount of drug that the neonate was exposed.


Production Schedule

Sites Performed
  • Quest - Chantilly
Days Performed
Monday
Tuesday
Wednesday
Thursday
Friday
Departments
  • Sendouts - Miscellaneous
Turn Around Time

2 days


Coding & Compliance

CDM

00917503


CPT Coding

80307